Tumor imaging and photothermal therapy in second near infrared window: A systematic review and meta-analysis

Fuhan Fan, Ya Hou, Yating Zhang, Yong Zeng, Yi Zhang, Sanyin Zhang, Xianli Meng, and Xiaobo Wang

Background: Second near-infrared window (NIR-II, 1000-1700 nm) technology for tumor imaging and photothermal therapy (PTT) is an innovative method for tumor diagnosis and treatment. The NIR-II probe can specifically identify tumor cells, and effectively convert light energy into heat energy under the irradiation of NIR laser, thus achieving the integration of non-invasive tumor diagnosis and treatment. In the present study, we conducted a systematic review and meta-analysis of preclinical investigations to corroborate the efficacy and safety of photothermal therapy.

Methods: Relevant preclinical data were retrieved by searching PubMed, Web of Science, CNKI, WANFANG and VIP information databases. And the acquired data were analyzed by RevMan Version 5.3 software.

Results: According to the inclusion criteria, forty-two articles relating to NIR-II tumor imaging and PTT were recruited for further in-depth analysis. The NIR-II probe can specifically identify tumor cells, and effectively convert light energy into heat energy under the irradiation of NIR laser, thus achieving the integration of non-invasive tumor diagnosis and treatment. In the present study, we conducted a systematic review and meta-analysis of preclinical investigations to corroborate the efficacy and safety of photothermal therapy.

Conclusions: PTT guided by NIR-II imaging can effectively diagnose the tumor lesion and eliminate it with the advantages of non-invasive and higher biosafety.
Introduction

Tumor is a form of disease with excessive mortality globally with no effective and completely acceptable techniques for its cure and prognosis (1). Conventional non-invasive medical imaging devices, such as computed tomography (CT), magnetic resonance imaging (MRI), ultrasound (US) and positron emission tomography (PET) (2), have made some achievements in the detection of diversified tumors. However, the problems of low resolution, shallow imaging depth and inevitable radiation still force human beings to hunt for novel clinical imaging methods, which stimulate a new development in optical imaging. It is well worth noting that photons for biological imaging in visible light window will be scattered and absorbed by blood, fat and hemoglobin in organic tissues, making it difficult to photograph deep tissues (3). As a result, near-infrared (NIR) imaging and therapeutic methods with robust tissue penetration and small photons scattering have been swiftly developed in current years. Imaging guided via the first near infrared window (NIR-I, 700-900nm) and the NIR-II window is the predominant direction of NIR imaging (4).

In addition, some NIR probes can additionally be used as photothermal agents (PTA) to achieve photothermal therapy (PTT) of tumor cells under the irradiation of NIR laser (6). PTT is a cure approach that kills tumor cells by way of heating up the local tumor tissue. It has been reported that irreversible injury can be brought about to tumor cells when the temperature exceeds 43°C (7). The tumor site was accurately located by NIR-II imaging system via certain NIR laser irradiation to the tumor tissue. In principle, PTA can activate from ground state to certain NIR laser irradiation, and then collide with surrounding molecules to generate kinetic energy and eventually convert into heat to kill tumor cells (8). After a persistent period of photothermal treatment, blood and major organs of tumor model mice were collected for blood routine and H&E staining analysis. It was suggested that a mass of the tumor cells went into apoptosis with no distinct difference in normal tissue and blood routine indexes between PTT-treated mice and normal mice (9, 10). Compared with traditional surgical resection for tumor treatment, NIR-II guided tumor imaging and PTT exhibit much less biological trauma and higher specificity (11), which was promising to be a novel approach for clinical treatment of tumors. The principles of tumor localization and photothermal treatment guided by NIR-II imaging are shown in Figure 1.

At present, NIR-II fluorescence imaging has made a great breakthrough in guiding clinical tumor resection. With the advantages of real-time imaging and wide field of view, it can provide dynamic feedback of tumor area information in the course of surgery. More accurately, numerous evidence demonstrated that NIR-II imaging can detect tumor signals that cannot be identified by CT imaging (12). Based on the achievements of NIR-II imaging in cancer surgery and the encouragement of preclinical data on photothermal treatment, we believe that NIR-II imaging guided PPT has a bright future in clinical cancer diagnosis and treatment. Due to the lack of relevant clinical data, we conducted a systematic review and meta-analysis of the preclinical data of PTT, providing more powerful evidence for its efficacy and safety.

Methods

Literature search

Two researchers (FF and YH) used PubMed, Web of Science, China National Knowledge Infrastructure (CNKI), WANFANG, and VIP Journal database to conduct a comprehensive search for publications up to January 10, 2022. The following is the literature search algorithm: (second near infrared OR NIR-II) AND (cancer OR tumor) AND (photothermal therapy OR PTT). In addition, there are no other relevant restrictions in the retrieval of literature search.

Study selection

All the literatures were retrieved by the above programmed algorithm and were input into reference management software for unified management. Firstly, articles were preliminarily screened according to the title and abstract, and then the full context was read to cautiously consider whether to be subordinated to our study. Article selection criteria were carefully determined and strictly enforced during the study selection process. Studies were included when they conformed all of the following criteria: 1) Use of NIR-II imaging to locate tumors and cancer cells; 2) PTA related characterization; 3) Photothermal tests were carried out on mice using NIR-II imaging system, and data related to the efficacy and safety of PTT were obtained. Meanwhile, studies were excluded if they accorded with any of the following criteria:1) One of a range of reviews, case reports, conference articles, abstracts, social reviews, and clinical literature; 2) None of experimental study; 3) None of NIR-II imaging; 4) None of records associated to the characteristic of PTA; 5) None of information related to tumor imaging; 6) None of data related to PTT; 7) Duplicate publications.
Data extraction and quality evaluation

The process of information extraction was mutually performed by two reviewers (FF and YZ). Pre-defined information extraction strategies were employed for effective extraction, and the differences between reviewers were resolved by consensus. The required data was extracted as comprehensively as possible from the included article, including text material and charts as sources of information. However, when solely charts were available in the article, the applicable information was thus obtained quantitatively on the charts using the line length tool in PowerPoint (13). The essential information collected were as follows: first author and publication time, basic information of the PTA, bioactivity of the probe, tumor imaging ability, in vitro tissue signals, in vitro and in vivo photothermal conversion parameters of the PTA, grouping and sample size, photothermal treatment conditions, and volume change of tumor after PTT.

The quality of the studies was evaluated through scoring 10 indicators in the preclinical research quality evaluation table: 1) Whether the articles were published after peer review; 2) Whether there is a description of temperature control; 3) Whether animal groups are randomly assigned; 4) Whether to follow the allocation hiding; 5) Whether the outcome indicators were evaluated by blind method; 6) Whether anesthetics with neuroprotective properties are used; 7) Whether animal models with comorbidities are used; 8) Whether to specify the sample size; 9) Whether there is a declaration of animal welfare regulations (10); Whether there is a conflict of interest related declaration. When there is a description in the article that conforms to the relevant indicators, it will get one point under this indicator. Otherwise, it will no longer get point. The ultimate rating of the paper was 0-10, with higher scores indicating more rigorous methodological design of research.

Statistical analysis

RevMan version 5.3 software was used for data summary and analysis. Dichotomous variable method was used to characterize the efficacy of PTT in tumor treatment. The random-effects model and 95% confidence interval (CI) risk ratio (RR) were used to show the association. The continuous variable method was used to characterize the safety of PTT. Fixed effect model and mean difference (MD) of 95% CI were used to evaluate the changes of specific blood routine indexes. The I² statistical test was used to test the heterogeneity of individual studies. When I²>50% of the time, we thought the study had significant heterogeneity. While the probability value less than 0.05 was considered statistically significant.

Results

Literature search

A total of 6299 related studies were obtained from the target database by the predefined search algorithm. And 5924 articles were retrieved by excluding duplicate articles. By reading the title and abstract of the articles, 5860 articles that did not conform the requirements were initially excluded, including 309 non-experimental articles, 120 informal articles (news reports and comments), 2860 articles that did not involve NIR-II imaging, 2338 articles that did not contain tumor imaging, and 134
articles that did not use PPT. The remaining 64 studies were then screened and evaluated through full-text reading, and 22 papers were further excluded. Finally, 42 related studies were included in the meta-analysis (7–10, 14–51). The retrieval and selection process of the article is shown in Figure 2.

Study characteristics

Different kinds of probes have widespread differences in the outcomes of PTT. We sorted out the essential traits of the probes concerned in the studies (Table 1), including excitation wavelength, quantum yield (QY) and extinction coefficient (ε), et al. Due to the innovativeness of NIR-II image-guided PTT utilized to tumors treatment, all the included studies were published in latest years (2018 to 2021) and were preclinical researches. The type of probe imaging comprised NIR-II fluorescence imaging (21 researches), NIR-II photoacoustic imaging (6 researches), and NIR-II fluorescence photoacoustic dual-mode imaging (15 researches). The probes involved in each study were reported for the first time and were no longer reproducible with each other.

The emission wavelength, QY and ε of the probe are considered as vital elements affecting the fluorescence brightness of the probe. QY refers to the fluorescence conversion rate of fluorescent probe after absorption of photons (52). Included in the literature studied in this paper, the highest QY of the probe is 3.78% (51), while the lowest is 0.004% merely (30). Almost all of the probes involved in the studies had the maximum emission peak in the NIR-II region, despite of a few of the probes (37, 40, 43) with no maximum emission peak in the NIR-II region, but still had a large amount of fluorescence emission in this region. The ε of the probe at the maximum emission wavelength was further measured, and the maximum and minimum ε of the articles included in this paper were 130.3 and 2.01 L/cm·g (14, 24), respectively. In addition, the cell viability of probes with different concentrations and related cells cultured for a certain period of time was calculated as the important biosafety evaluation index of probes. The cell survival rate of the probes used in this study was above 80%, and the influence of some probes on cell activity even could be ignored (16, 24, 26, 46, 49).

Tumor imaging capability of NIR-II

The probe is the basis of PTT for high-precision imaging of tumors in the NIR-II imaging system. In this regard, we thus sorted out the imaging information of different probes in Table 2. The capacity of the probe to image tumor can be expressed by the time of the maximum signal of NIR-II fluorescence imaging or photoacoustic imaging, and the ratio of the maximum signal to the initial signal. The shorter time of the maximum signal intensity indicated the stronger selectivity of the probe to the tumor. And the larger ratio of the maximum signal to the initial signal manifested the potential of imaging to a certain extent. In this paper, the maximum signal time of the fluorescent probe is mostly 12 h and 24 h, the shortest and longest time are 3 h (49) and 5 d (44) respectively. Noteworthily, the ratio of the maximum signal to the initial signal can be enhanced up to 15 times (40). Most of the time of the maximum signal of the photoacoustic probe is between 6-24 h with the ratio of the maximum signal to the initial signal up to about 13 times (17, 47).

In general, intravenously injected probes can image biological blood vessels to varying degrees. The smaller the visualized vessels by NIR-II imaging system indicates the higher accuracy of the probe to some extent. Most of the probes

![Flow chart of study selection.](image-url)
| Study       | Names           | Shape     | Size (nm)     | Type | A<sub>max</sub> (nm) | E<sub>max</sub> (nm) | QY (%) | ε (L/g.cm) | Cells Administration | Viability |
|------------|----------------|-----------|---------------|------|---------------------|---------------------|--------|-------------|----------------------|-----------|
| Zhang 2021 | SH-PEG-FA      | Flake     | 37.6×1.5      | PAI  | NR                  | 785, 1064           | NR     | 32.58 (808 nm), 27.85 (1064nm) | HeLa (0–150 μg/ml, 24 h) | 76%, 82%   |
| Dai 2021   | Lip (DPQ+zIDG) | Sphere    | 100           | FI   | 1015                | 1300                | 0.02   | 26.7 (1064nm) | 4T1 (0–625 μg/ml, 24 h) | 75.03%    |
| Li 2020    | FS-GdNds       | NR        | 9.3 ± 0.5     | FI   | NR                  | NR                  | NR     | NR          | 4T1 (0–5 μg/ml, NR) | 85%       |
| Wang 2019  | N-B-GQDs       | NR        | 4.7           | FI   | NR                  | 1000                | 1.00   | NR          | 4T1 (0–500 μg/ml, 72 h) | 94%       |
| Zheng 2021 | HSC-2          | Jujube    | 142.2         | PAUI| NR                  | 957                 | 0.41   | 2.01        | 4T1 (0–400 μg/ml, 24 h) | 85%       |
| Zheng 2020 | Ag3S-GOx@BHS   | Sphere    | 9.17          | FII  | NR                  | NR                  | NR     | NR          | 4T1 (0–1000 μg/ml, 24 h) | 75%       |
| Zheng 2020 | Bi2S3-Ag2S-DATS@BGA-N3 | Sphere | 8.8 ± 1.2     | FII  | 900                 | 1000                | NR     | NR          | Hep2 (0–600 μg/ml, 12 h) | 98.23%    |
| Zhan 2020  | QT-RGD         | Sphere    | 34.7 ± 0.6    | PAI  | 1042, 841           | 1068                | 0.12   | NR          | 4T1 (0–20 μM, 24 h) | >85%      |
| Zhang 2020 | TSSI NPs       | Sphere    | 40            | FI   | NR                  | NR                  | NR     | 27.2 (785 nm), 3.1 (1064 nm) | 4T1 (0–50 μg/ml, 24 h) | >96%      |
| Zhang 2020 | PSQPNs-DBCO    | Sphere    | 35 ~ 85       | FI   | 1064                | 1290                | NR     | NR          | NR                   | NR        |
| Zhang 2019 | SPN3           | Sphere    | 43 ~ 57       | PAI  | 899, 1000, 1300     | 1280                | 2.54 (1064 nm) | 4T1 (0–50 μg/ml, 48 h) | 94%       |
| Yin 2019   | OSPA           | Sphere    | 69.7 ± 2.3    | PAI  | 1000                | NR                  | 18 (980 nm) | 4T1 (0–0.3 mg/ml, NR) | >90%      |
| Yang 2020  | L1057 NPs      | Sphere    | 51            | FI   | 470, 937            | 1057                | 1.25   | NR          | 3T3 (0–50 μg/ml, 24 h) | >85%      |
| Xie 2021   | PFG MPNs       | Sphere    | 80            | FI   | 826                 | 1063                | NR     | NR          | LO2 (0–50 μg/ml, 24 h) | >90%      |
| Wang 2019  | PEG-CSS@PB     | Sphere    | 164           | FI   | 1525                | NR                  | NR     | NR          | HeLa (0–600 μg/ml, 24 h) | >100%     |
| Sun 2021   | TTO-MnCO NPs   | Sphere    | 120           | FI   | 1115                | NR                  | NR     | MCF-7 (0–0.1 mg/ml, 24 h) | 95%       |
| Sun 2020   | MNPH2          | NR        | NR            | FII  | 609, 1006           | 0.20                | NR     | NR          | Hep-2 (0–800 μg/ml, NR) | >100%     |
| Shi 2018   | Nano-PT        | NR        | NR            | FII  | 790                 | NR                  | 130.3 (750 nm) | HCT116 (0–20 μM, NR) | 96%       |
| Li 2021    | ETTC NPs       | Sphere    | 59.3          | FI   | 750                 | NR                  | 3.00   | NR          | A549 (0–50 μg/ml, 24 h) | 90%       |
| Li 2019    | NaLuF4 NR0@PDA | Slavate   | 20 × 130      | FI   | NR                  | 1525                | 1.37   | 5.09×10<sup>7</sup> (M<sup>2</sup>cm<sup>−1</sup>) | HeLa (0–1000 μg/ml, 24 h) | 87%       |
| Li 2019    | PF             | NR        | 90            | FI   | 1026                | 1064                | 0.30   | NR          | 4T1 (0–2.5 μg/ml, 24 h) | 85%, 91%   |
| Li 2021    | Pry-Ps@CP-PEG  | Sphere    | 80            | FI   | 900                 | 1140                | 2.20   | NR          | HeP2G2 (0–2.5 μg/ml, 24 h) | >90%      |
| Li 2019    | PFTDPP-SNAP NPs| NR        | NR            | PAI  | NR                  | 1060                | 1.8    | NR          | MCF-7 (0–1 mg/ml, NR) | >90%      |
| Li 2021    | B8TD-BET       | Sphere    | 29 ± 3        | FI   | 780                 | 1094                | 0.004  | NR          | MCF-7 (0–800 μg/ml, 24 h) | >90%      |
| Hu 2019    | PFTQ-PEG-Gd NPs| Sphere    | 105           | FI   | 1056                | 10.36 (1064 nm)     | 0.38   | 10.36 (1064 nm) | NIH/3T3 (0–120 μg/ml, 24 h) | 88%, 91%, 90% |

(Continued)
included in this meta-analysis were able to image mice blood vessels with a diameter of about 0.4 mm (8, 17, 35, 36), while some even reached ~1.9 μm with a high-magnification imaging system (22). In addition, the blood vessels interacting with tumor tissues can be clearly observed by high-power imaging systems (29), which is of great merit for monitoring tumor changes during PTT. In most studies, signal intensities in tumor blocks, liver and spleen were highest at 12 h, 24 h, and 48 h (8, 9, 14–16, 18, 22, 28, 32–34, 36, 42), which then began to decline continuously. This indicates that the involved probes have higher selectivity for tumor and specific tissues. And the accumulated probe is excreted mainly through the hepatobiliary system.

Effect of PTT guided by NIR-II imaging

The effect of periodic PTT is ultimately reflected in the actual change of tumor volume. In order to further analyze the effect of photothermal treatment, we collated the photothermal information of different PTA and the detailed changes condition of tumor in vivo (Table 3). Among the included studies, there were 17 items whose PTA photothermal conversion efficiency was greater than 40%, 20 items whose probe photothermal conversion efficiency was lower than 40%, and 6 items had no relevant records. PTT typically makes use of 1.0 W/cm² at 1064 nm (8, 14, 19, 20, 21, 25, 35–37, 46, 47) and 1.0 W/cm² at 808 nm (15–17, 23, 24, 26, 28, 31, 32, 34, 39, 42) NIR
| Study            | Animal                        | Probe dose            | PAI of tumor | FI of tumor | Ac     | In vitro tissue signal                      |
|------------------|-------------------------------|-----------------------|--------------|-------------|--------|---------------------------------------------|
| Zhang 2021 (7)   | NR                            | NR                    | NR           | NR          | NR     | NR                                          |
| Dai 2021 (8)     | NR                            | 800 µg/ml, iv.        | NR           | 24 h, 6.7 times | 0.402 mm | Liver>spleen>tumor, 48 h                     |
| Li 2020 (9)      | Female BALB/c nude mice       | NR                    | NR           | 12 h, NR    | NR     | Liver>spleen>tumor, 24 h                     |
| Wang 2019 (10)   | Nude mice                     | 1 mg/ml 200 µl, iv.   | NR           | NR          | 130 µm | Liver>kidney>spleen, 24 h                   |
| Zheng 2021 (14)  | NR                            | 20 mg/kg, iv.         | 12 h, 10 times | 12 h, 8.34 times | NR     | Liver>tumor>spleen, 24 h                     |
| Zheng 2020 (15)  | BALB/c nude mice, 15-17 g     | 20 mg/kg, iv.         | 8 h, 7.5 times | 8 h, 9.4 times | NR     | Liver>tumor>spleen, 24 h                     |
| Zheng 2020 (16)  | Female BALB/c nude mice, 6-8 w, 18-20 g | 15 mg/kg, iv.   | 6 h, NR     | 6 h, NR     | NR     | Liver>tumor>spleen, 24 h                     |
| Zhao 2020 (17)   | BALB/c mice                   | 100 µM 200 µl, iv.    | 8 h, 13.8 times | 5 h, 3.6 times | 0.43 mm | Tumor>kidney>liver, 24 h                     |
| Zheng 2020 (18)  | BALB/c nude mice              | NR                    | 12 h, NR    | NR          | NR     | Liver>spleen>tumor, 24 h                     |
| Zhang 2020 (19)  | BALB/c mice, 6 w              | 2 mg/ml 100 µl, iv.   | NR           | NR          | NR     | NR                                          |
| Zhang 2019 (20)  | NR                            | 1 mg/ml 100 µl, iv.   | 10 h, 2 times | NR          | NR     | NR                                          |
| Yin 2019 (21)    | NR                            | NR                    | 6 h, 8 times | NR          | NR     | Liver, 24 h                                 |
| Yang 2020 (22)   | NR                            | 500 µg/kg 80 µl, iv.  | 48 h, 4.3 times | NR          | 1.9 µm | Liver>tumor>spleen, 48 h                     |
| Xie 2021 (23)    | C57BL/6 mice, 6-8 w, 18 ± 2 g | NR                    | 24 h, 4.1 times | 24 h, 6.7 times | NR     | Liver>spleen, 24 h                          |
| Wang 2019 (24)   | Female BALB/c mice            | 0.5 mg/ml, iv.        | NR           | NR          | NR     | NR                                          |
| Sun 2021 (25)    | NR                            | 2 mg/ml 150 µl, iv.   | 24 h, 8 times | 0.35 mm     | NR     | Spleen>liver>tumor, 26 h                     |
| Sun 2020 (26)    | BALB/c mice, 6-8 w, 18-20 g   | 800 µg/ml 200 µl, iv. | 8 h, 2.9 times | 8 h, 2.2 times | NR     | Liver>kidney>tumor, 24 h                     |
| Shi 2018 (27)    | NR                            | NR                    | 2 h, NR     | NR          | NR     | NR                                          |
| Li 2021 (28)     | Female BALB/c mice, 3-6 w     | 1 mg/ml 200 µl, iv.   | 12 h, 6.8 times | 12 h | NR     | Liver>spleen>tumor, 12 h                     |
| Li 2019 (29)     | NR                            | 0.2 mg/ml 0.2 ml, iv. | NR           | NR          | 45 µm | Liver>tumor, 60 h                           |
| Li 2019 (30)     | BALB/c mice                   | NR                    | 12 h, NR    | NR          | NR     | Liver>lung>kidney, 24 h                      |
| Li 2021 (31)     | 4 mg/ml 200 µl, iv.           | NR                    | 24 h, NR    | NR          | NR     | NR                                          |
| Li 2019 (32)     | Female BALB/c mice, 4-5 w     | 1 mg/ml, iv.          | 24 h, 24 h   | NR          | NR     | NR                                          |
| Li 2021 (33)     | 10 mg/ml 200 µl, iv.          | NR                    | 12 h, NR    | 0.675 mm    | NR     | Liver>tumor>liver, 24 h                      |
| Hu 2019 (34)     | NR                            | 1 mg/ml 150 µl, iv.   | 24 h, 4.5 times | 24 h, NR    | NR     | Spleen>liver>tumor, 24 h                     |
| Dai 2021 (35)    | NR                            | NR                    | 24 h, 9.3 times | 24 h, 4.2 times | 0.42 mm | Spleen>liver>tumor, 24 h                     |
| Chen 2021 (36)   | 2 mg/ml 100 µl, iv.           | NR                    | 24 h, 2.8 times | 0.4 mm     | NR     | Spleen>tumor>liver, 24 h                     |
| Jia 2021 (37)    | Female Nude mice, 20 g        | 20 mg/kg, iv.         | 12 h, NR    | NR          | NR     | NR                                          |
| Qian 2021 (38)   | Female BALB/c mice, 5 w       | 8 mg/kg 150 µl, iv.   | 12 h, 8 h, NR | 0.705 mm    | NR     | Liver, 8 h                                 |
| Guan 2021 (39)   | Female BALB/c mice, 6 w       | 20 µg/ml 200 µl, iv.  | NR           | 24 h, NR    | NR     | Tumor>lung>liver, 48 h                       |
| Xia 2020 (40)    | NR                            | 2 mg/ml 100 µl, iv.   | NR           | 20 h, 2.8 times | NR     | NR                                          |
| Xu 2020 (41)     | NR                            | NR                    | 20 h, 15 times | 24 h, 9.4 times | NR     | Liver>spleen>tumor, 72 h                     |
| Zhu 2020 (42)    | Female BALB/c mice, 18-20 g   | NR                    | 24 h, 10.5 times | 48 h, NR    | NR     | Liver>spleen>tumor, 24 h                     |
| Yao 2020 (43)    | NR                            | 5 mg/kg, iv.          | 12 h, NR    | NR          | NR     | NR                                          |
| Wang 2019 (44)   | BALB/c mice                   | 0.25 mg/ml 50 µl, iv. | 12 h, NR    | 5 d, NR     | NR     | Liver>kidney>spleen, 21 h                    |
| Meng 2018 (45)   | Female BALB/c mice, 6-8 w, 15-20 g | 40 µg/ml 200 µl, iv. | NR           | 14 h, NR    | NR     | Tumor>lung>liver, 14 h                       |
| Zheng 2021 (46)  | Female BALB/c mice, 6-8 w, 17-19 g | 15 mg/kg, iv.       | 14 h, NR    | NR          | NR     | NR                                          |
| Huang 2020 (47)  | BALB/c mice                   | 2 mg/ml 100 µl, iv.  | 12 h, 13.4 times | 12 h, 3.8 times | NR     | NR                                          |
| Zhou 2020 (48)   | Female BALB/c nude mice, 6 w  | 400 µg/ml 200 µl, iv. | NR           | 12 h, NR    | NR     | Liver, 48 h                                |

(Continued)
light sources to irradiate the tumor site. And a few studies also choose other light sources according to the properties of PTA [e.g., 0.1 W/cm² at 980 nm (45), and 1 W/cm² at 915 nm (38)]. The PTA with excellent photothermal conversion efficiency can make the tumor heat up rapidly in a short time after feeling the NIR laser irradiation. The maximum temperature of PTA was higher than 43 °C in 31 studies, which could theoretically cause irreversible injury to tumors. Under the continuous photothermal treatment with a general period of 14 to 30 days, the tumor necrosis was gradually accompanied by a marked reduction in size.

Finally, we used the forest plot to analyze the curative effect of PTT based on the proportion of tumor cured cases to the total sample size. The total sample size of individual studies and the number of cases with different efficacy were further calculated by reviewed the included studies and the supplementary literatures. Of the 42 studies, 11 items confirmed that tumors could be completely ablated by photothermal treatment (15–18, 30, 33, 38, 48–51). And 20 items showed conspicuous reduction in tumor size but not complete elimination (8, 15, 16, 19, 20, 23, 25, 30, 32, 34–36, 38–41, 47, 48, 50, 51). Compared with the control group, tumors treated with periodic PTT could eventually be completely ablated with some degree of crusting (n=108, RR=7.01, 95%CI (3.04, 16.13), P<0.00001; Heterogeneity: Tau² - 0.00, Chi² - 1.93, df=10 (P=1.00), I² - 0% (Figure 3A). At the same time, though most of the PTA did not completely ablate the tumor with the aid of PTT, but the tumor volume exhibited a prominent trend of reduction comparing with initial size (n=188, RR=8.49, 95%CI (4.64, 15.55), P<0.00001; Heterogeneity: Tau² - 0.00, Chi² - 1.62, df=19 (P=1.00), I² - 0% (Figure 3B).

Safety evaluation of PTT

Blood routine test can reflect the pathological changes of the body by observing the changes in the number and distribution of blood cells. In this study, 11 researches measured the blood routine of animals after PTT, and the main indexes were WBC, RBC, HGB, MCV, MCH and MCHC (7, 17–20, 22, 27, 28, 33, 34, 50). Unfortunately, we solely obtained detailed data from four researches for meta-analysis (7, 18, 33, 50), two of which were tumor mice (7, 18) and two were healthy mice (33, 50). Through data analysis, it was found that the blood routine indexes except WBC were mostly within the reference range, indicating that PTT has high security for tumor treatment.

In order to analyze the particular changes of relevant indicators, we conducted a forest plot on the data of four researches. The changes of WBC [n=34, MD=-0.63, 95%CI (-1.45, 0.19), P=0.13; Heterogeneity: Chi² - 13.69, df=3 (P=0.003), I² - 78%] (Figure 4A) and MCV [n=34, MD=-0.42, 95%CI (-1.34, 0.49), P=0.36; Heterogeneity: Chi² - 18.85, df=3 (P=0.001), I² - 81%] levels in mice after periodic PTT had no effect (Figure 4B). The changes of RBC level in tumor mice showed no distinction from the control group, while reduced slightly in healthy mice [n=34, MD=-0.28, 95%CI (-0.53, -0.03), P=0.03; Heterogeneity: Chi² - 1.84, df=3 (P=0.61), I² - 0%] (Figure 4C). Although the trend of MCH level was different in tumor mice and healthy mice, the final aggregate effect showed no difference with the control group [n=34, MD=-0.21, 95%CI (-0.57, 0.14), P=0.24; Heterogeneity: Chi² - 9.71, df=3 (P=0.02), I² - 69%] (Figure 4D). MCHC levels were down regulated in both tumor and healthy mice after periodic PTT [n=34, MD=-14.99, 95%CI (-18.86, -11.12), P<0.00001; Heterogeneity: Chi² - 3.32, df=3 (P=0.34), I² - 10%] (Figure 4E).

Quality score

The 42 studies were evaluated according to the study quality evaluation index of preclinical research, and the average score of 6.52 is shown in Table 4. The overall score of the researches ranged 3–9, among which 23 studies scored higher than 7 (8–10, 15, 16, 19, 21, 22, 24–26, 28, 29, 32–34, 38, 44–46, 48–50), and 19 studies scored between 3–6 (7, 14, 17, 18, 20, 23, 27, 30, 31, 35–37, 39–43, 47, 51). The main factors causing the subtraction of the research were lack of description of temperature, types of narcotic drugs, and randomization information.

Discussion

According to relevant reports, cancer has long remained the leading cause of death worldwide (53), such as breast cancer (54), lung cancer (55), liver cancer (56), and colon cancer (57). Traditional clinical diagnosis and treatment measures can no longer meet the needs of precise targeted therapy and even
| Study               | In vitro photothermal capacity | \( \eta \) (%) | Administration | Conditions of PTT | \( V_0 \) (mm³) | Times (h) | Days (d) | \( \Delta T \) (°C) | \( T_{\text{max}} \) (°C) | Effect |
|---------------------|--------------------------------|----------------|----------------|-------------------|----------------|-----------|----------|-----------------|------------------------|--------|
| Zheng 2020 (7)      | 100 μg/ml, 1064 nm, 6 min, \( \Delta T=28°C \) | 45.7           | NR             | NR                | NR             | NR        | NR       | 21              | 20.2                   | 50.2   |
| Dai 2021 (8)        | NR, 1064 nm, 5 min, \( \Delta T=45.4°C \) | 40.92          | 800 μg/ml      | 1064 nm, 1.0 W/cm² | NR             | 24        | 15       | 21.5            | 50                     | †      |
| Li 2020 (9)         | 5 μg/ml, 808 nm, 10 min, \( \Delta T=15.8°C \) | 43.99          | 3.5 mg/kg      | 808 nm, 0.96 W/cm² | NR             | 12        | 16       | 18.1            | 49.1                   | –      |
| Wang 2019 (10)      | 200 μg/ml, 808 nm, 5 min, \( \Delta T=26.6°C \) | 32.32          | 1 mg/mL, 200 μl | 808 nm, 1.5 W/cm² | NR             | NR        | NR       | NR             | NR                     | †      |
| Zheng 2021 (14)     | 400 μg/ml, 1064 nm, 5 min, \( \Delta T=34°C \) | 41.4           | 20 mg/kg       | 1064 nm, 1.0 W/cm² | 80             | 12        | 10       | 17.5            | –                      | –      |
| Zheng 2020 (15)     | NR                                            | NR             | 20 mg/kg       | 808 nm, 1.0 W/cm² | 100            | 8         | 15       | 22.5            | 58.5                   | †      |
| Zheng 2020 (16)     | 600 μg/ml, 808 nm, 5 min, \( \Delta T=36.9°C \) | 31.60          | 15 mg/kg       | 808 nm, 1.0 W/cm² | 100            | 6         | 20       | 17.5            | –                      | –      |
| Zhao 2020 (17)      | 36.50 100 μM 200 μl                          | 36.50          | NR             | 808 nm, 1.9 W/cm² | 20             | 4         | 21       | 21.7            | NR                     | –      |
| Zhang 2020 (18)     | 100×10⁻⁷ m, 660 nm, 5 min, \( \Delta T=28°C \) | 46             | NR             | 660 nm, 0.3 W/cm² | NR             | 12        | 15       | 17.5            | 54.8                   | –      |
| Zhang 2020 (19)     | 125 μg/ml, 1064 nm, 5 min, \( \Delta T=50°C \) | 33.4           | 2 mg/ml 100 μl | 1064 nm, 1.0 W/cm² | NR             | 24        | 15       | NR             | NR                     | †      |
| Zhang 2019 (20)     | 25 μg/ml, 1064 nm, 400 s, \( \Delta T=44.5°C \) | 60             | 1 mg/ml 100 μl | 1064 nm, 1.0 W/cm² | NR             | 10        | 15       | 45              | 75.2                   | †      |
| Yin 2019 (21)       | 0.8 mg/ml, 1064 nm, 6 min, \( \Delta T=59.5°C \) | 30.53          | NR             | 1064 nm, 1.0 W/cm² | 100            | 6         | 14       | 26.2            | 58.2                   | –      |
| Yang 2020 (22)      | 100 μg/ml, 980 nm, 500 s, \( \Delta T=27.3°C \) | 38             | 500 μg/kg 80 μl | 980 nm, 0.72 W/cm² | 100            | 1         | 14       | 24              | 58                     | †      |
| Xie 2021 (23)       | 0.25 mg/ml, 880 nm, 10 min, \( \Delta T=73°C \) | 75.60          | NR             | 808 nm, 1.0 W/cm² | 80             | 24        | 14       | 18.5            | 50                     | †      |
| Wang 2019 (24)      | 600 μg/ml, 808 nm, 10 min, \( \Delta T=23°C \) | 50.50          | 0.5 mg/ml      | 808 nm, 1.0 W/cm² | 90             | NR        | 13       | NR             | 42                     | †      |
| Sun 2021 (25)       | 0.10 mg/ml, 1064 nm, 5 min, \( \Delta T=44.8°C \) | 44.43          | 2 mg/ml 150 μl | 1064 nm, 1.0 W/cm² | NR             | NR        | 15       | 23.5            | 56                     | †      |
| Sun 2020 (26)       | 200 μg/ml, 808 nm, 5 min, \( \Delta T=30.8°C \) | NR             | 800 μg/ml 200 μl | 808 nm, 1.0 W/cm² | 100            | 8         | 16       | 25              | 59.2                   | –      |
| Shi 2018 (27)       | NR, 10 min, \( \Delta T=32°C \)               | 27.80          | NR             | 785 nm, 1.66 W/cm² | NR             | 2         | 15       | 30.9            | 60.9                   | –      |
| Li 2021 (28)        | 50 μg/ml, 808 nm, 8 min, \( \Delta T=58°C \)  | 52.80          | 1 mg/ml 200 μl | 808 nm, 1.0 W/cm² | 100            | 12        | 14       | 27              | NR                     | –      |
| Li 2019 (29)        | 0.2 mg/ml, 808 nm, 10 min, \( \Delta T=34°C \) | 40.18          | 0.2 mg/ml 0.2 ml | 808 nm, 10 min   | 100            | NR        | 12       | NR             | NR                     | –      |
| Li 2019 (30)        | 25 μg/ml, 808 nm, 5 min, \( \Delta T=29.8°C \) | 42.30          | NR             | 808 nm, 0.65 W/cm² | 150            | 1         | 21       | 20.3            | 51.8                   | –      |
| Li 2021 (31)        | 1 mg/ml, 808 nm, 5 min, \( \Delta T=47°C \)   | 43.70          | 4 mg/ml 200 μl | 808 nm, 1.0 W/cm² | 80             | 24        | 15       | 31.5            | NR                     | –      |
| Li 2019 (32)        | 2 mg/ml, 808 nm, 10 min, \( \Delta T=60°C \)  | 48             | 1 mg/ml       | 808 nm, 1.0 W/cm² | NR             | 24        | 21       | 28              | 60                     | –      |
| Li 2021 (33)        | 2 mg/ml, 808 nm, 5 min, \( \Delta T=45.7°C \) | 39.42          | 10 mg/ml 200 μl | 808 nm, 0.3 W/cm² | 100            | 12        | 14       | 21              | 56                     | –      |
| Hu 2019 (34)        | 500 μg/ml, 808 nm, 10 min, \( \Delta T=44°C \) | 26             | 1 mg/ml 150 μl | 808 nm, 1.0 W/cm² | 80             | 24        | 16       | 25              | 58.5                   | †      |
| Dai 2021 (35)       | 80 μg/ml, 1064 nm, 5 min, \( \Delta T=45.8°C \) | 39.24          | NR             | 1064 nm, 1.0 W/cm² | NR             | 24        | 14       | 18              | NR                     | †      |
| Chen 2021 (36)      | 40 μg/ml, 1064 nm, 400 s, \( \Delta T=25°C \) | 55.10          | 2 mg/ml 100 μl | 1064 nm, 1.0 W/cm² | 100            | 24        | 15       | 20.7            | 53.2                   | †      |

(Continued)
TABLE 3 Continued

| Study          | In vitro photothermal capacity | η (%) | Administration | Conditions of PTT | V₀ (mm²) | Times (h) | Days (d) | ΔT (°C) | Tmax (°C) | Effect |
|----------------|--------------------------------|-------|----------------|-------------------|----------|-----------|----------|---------|-----------|--------|
| Jia 2021 (37)  | 400 µg/ml, 1064 nm, 5 min △T=34°C | NR    | 20 mg/kg       | 1064 nm, 1.0 W/cm², 5 min | 100      | 12        | 10       | NR      | NR        | –      |
| Qiu 2021 (38)  | 20 µg/ml, 915 nm, 5 min △T=24.2°C | 35.50 | 8 mg/kg 150 µl | 915 nm, 1.0 W/cm², 10 min | 100      | 8         | 15       | 21.7    | 48        | –      |
| Guan 2021 (39) | 20 µg/ml, 808 nm, 5 min △T=30°C | 12.91 | 20 µg/ml 200 µl | 808 nm, 1.0 W/cm², 5 min | 500      | 24        | 14       | 16.9    | 50.1      | –      |
| Xia 2020 (40)  | 100 µg/ml, 660 nm, 10 min △T=26°C | 23    | 2 mg/ml 100 µl | 660 nm, 0.3 W/cm², 10 min | 100      | 20        | 14       | NR      | 50        | †      |
| Xu 2020 (41)   | 100 µg/ml, 730 nm, 10 min △T=45°C | 50.00 | NR            | 730 nm, 1.0 W/cm², 10 min | NR       | 24        | 14       | NR      | 54        | †      |
| Zhu 2020 (42)  | 80 µM, 808 nm, 10 min △T=62°C | NR    | NR            | 808 nm, 1.0 W/cm², 10 min | 50       | 24        | 16       | 18.2    | 53.7      | †      |
| Yao 2020 (43)  | 1 mg/ml, 915 nm, 5 min △T=42.2°C | 25.60 | 5 mg/kg       | 915 nm, 0.5 W/cm², 5 min | NR       | 12        | 14       | 25.9    | 59.1      | –      |
| Wang 2019 (44) | 0.1 mg/ml, 915 nm, 6 min △T=40°C | 58.20 | 0.25 mg/ml 50 µl | 915 nm, 0.5 W/cm², 10 min | 120      | 6         | 15       | 48      | 68        | †      |
| Meng 2018 (45) | 100 µg/ml, 808 nm, 5 min △T=37°C | 20.20 | 40 µg/ml 200 µl | 980 nm, 0.1W/cm², 2 min | 100      | 14        | 30       | 30      | 57        | –      |
| Zheng 2021 (46)| 400 µg/ml, 1064 nm, 5 min △T=36°C | NR    | 15 mg/kg      | 1064 nm, 1.0 W/cm², 5 min | 75       | 12        | 12       | 17.89   | 51.9      | –      |
| Huang 2020 (47)| 1 mg/ml, 1064 nm, 5 min △T=35°C | NR    | 2 mg/ml 100 µl | 1064 nm, 1.0 W/cm², 5 min | 100      | 12        | 15       | 24.5    | 52        | †      |
| Zhou 2020 (48) | 64 µM, 808 nm, 12 min △T=30.5°C | 18    | 400 µg/ml 200 µl | 808 nm, 1.5 W/cm², 8 min | 800      | 12        | 14       | 34.8    | 67.8      | †      |
| Yang 2017 (49) | 1.0 mL, 808 nm, 5 min △T=35°C | 35.0  | 50.0 umol/kg  | 785 nm, 1.5 W/cm², 5 min | 60       | 24        | 30       | 19.0    | NR        | –      |
| Feng 2019 (50) | 500 µg/ml, 793 nm, 3 min △T=70.5°C | 32.74 | 2 mg/ml 100 µl | 793 nm, 2.0 W/cm², 10 min | 120      | 48        | 16       | 24.7    | 55.4      | †      |
| Zhao 2019 (51) | 600 µg/ml, 808 nm, 6 min △T=45°C | 21    | 150 µg/ml 100 µl | 808 nm, 2.5 W/cm², 10 min | 100      | NR        | 18       | 61.2    | 61.2      | †      |

†, tumor volume increases; ††, tumor reduced in size but did not disappear completely; -, complete tumor ablation; η, photothermal conversion efficiency; △T, tumor temperature changes after laser irradiation; Days, treatment cycle; NR, not report; Times, the time at which the NIR laser irradiation began after the probe was given; V₀, the initial volume of tumor.

Individualized treatment for these cancers (12). Although the commonly used measures PET, CT, MRI and US have made great achievements in tumor detection, the inevitable problems of low resolution, shallow imaging depth and certain radiation to organisms make people have to explore more excellent precise diagnosis strategies. Therefore, the optical imaging technology with high sensitivity and biological safety has been developed rapidly. Compared with visible light (400-700 nm) and NIR-I imaging, NIR-II technique with higher penetration depth and lower scattering has been generally accepted by researchers (10). It has been pronounced that the penetration depth of NIR-II imaging can reach more than 7 mm (58), contributing to identify and distinguish tiny tumors that cannot be discerned by traditional imaging strategies (59).

Conventional tumor diagnostic equipment is difficult to be integrated into the operating room and unable to provide real-time feedback of anatomical site information for aggressive surgery. Inconceivably, NIR-II guided tumor excision has conquered this conundrum in laboratory animals because of its wide imaging field and real-time feedback of tumor sites (60–62). Stupendously, the distinctive photothermal properties of some NIR-II probes enabled to convert light energy into heat under NIR laser irradiation, thereby inducing apoptosis of tumor cells. Robust evidence has manifested that NIR-II-guided PTT has unique advantages in accurate diagnosis and non-invasive treatment of tumors in comparison with chemotherapy and surgical resection (63).

Qualified NIR probes with good biocompatibility and excellent fluorescence performance can be divided into two categories: organic materials and inorganic materials. The former includes molecule fuels, aggregation induced emission molecules and nano-polymers, while the latter comprises quantum dots, single wall nanotubes and rare earth nanoparticles (64). The luminance of the contrast agent in the field and real-time feedback of tumor sites (60–62). Stupendously, the distinctive photothermal properties of some NIR-II probes enabled to convert light energy into heat under NIR laser irradiation, thereby inducing apoptosis of tumor cells. Robust evidence has manifested that NIR-II-guided PTT has unique advantages in accurate diagnosis and non-invasive treatment of tumors in comparison with chemotherapy and surgical resection (63).

Qualified NIR probes with good biocompatibility and excellent fluorescence performance can be divided into two categories: organic materials and inorganic materials. The former includes molecule fuels, aggregation induced emission molecules and nano-polymers, while the latter comprises quantum dots, single wall nanotubes and rare earth nanoparticles (64). The luminance of the contrast agent in the former includes molecule fuels, aggregation induced emission molecules and nano-polymers, while the latter comprises quantum dots, single wall nanotubes and rare earth nanoparticles (64). The luminance of the contrast agent in the
QY and photobleaching properties, but most of them have potential biological toxicity with the presence of toxic metal ions (65, 66). Although the biosafety of most organic fluorophores is better than that of inorganic materials, the short tumor residence time, low water solubility and QY prevent their widespread use. The lack of clinically approved NIR-II probes with high luminance and biosafety, and the inability to construct new PTA on this basis, is the main bottleneck that limits the development of PTT (67). However, the design philosophy based on structural modification and enhancement have made some progress in both safety and fluorescence properties of organic small molecules (68). A small molecule organic probe IR-820 (50) with high QY ($\epsilon = 30$ L/g·cm, QY=2.52%), reportedly showed unrivalled fluorescence brightness and could accurately image cerebral vessels at depth of 800 μm (Figure 5A). The semiconductor polymer L1057 NPs ($\epsilon = 18$ L/g·cm, QY=1.25%) can visualize 1.9 mm blood vessels under high power microscope (22). In addition, the probe NaLuF$_4$ NRS@PDA (29) with exceptional fluorescence emission and QY, can even illuminate the tiny blood vessels connected to the tumor with extreme clarity (Figure 5B).

The accuracy of NIR-II system in tumor diagnosis is determined by specific probes for tumor recognition. The massive accumulation of NIR-II probes at the tumor cell proclaimed intensive signal than that of surrounding tissue, which is conducive to the effective identification of tumors. Acknowledgedly, the local interactions between tumor cells and their adjacent tissues make tumor microenvironment (TME) slight acidity and overexpression of H$_2$O$_2$ (69). In the circumstances, Ag$_2$S-GOx@BHs NYS, a TME specific activated probe, accumulated and ignited heterogeneous tumor (15). As a crucial organelle of ion metabolism, mitochondria are also the focus of NIR-II probe design for targeted tumor imaging. H4-PEG-PT was successfully designed to selectively capture and track mitochondria of osteosarcoma cells with a subcellular resolution of 1 nM (48). In addition, the enhanced permeability and retention effect also provides an opportunity for NIR-II probe to light the tumor through aggregated luminescence, such as PCTA-BMA-OXA (42) and SPIO@NC (39).

The selection of laser light source, the time of laser irradiation and the period of treatment are all considered as potential factors during PTT. In order to reduce the injury of laser to skin, the photothermal treatment generally chooses the laser with lower than maximum permissible exposure (33) as the irradiation light (e.g., 0.3 W/cm$^2$ at 808 nm and 1 W/cm$^2$ at 1064 nm). In the analysis of this paper, it was found that the start time of laser irradiation was generally determined by the emergence time of the maximum fluorescence or photoacoustic signal of the probe in vivo. The photothermal transformation of the probe could be achieved to the maximum extent when the accumulation quantity of the probe reached the utmost in the tumor tissue (Figures 5C–F). As a PTA converting light energy...
into heat to kill tumor cells, no applicable rules declared the period of PTT in the included studies, which should be further investigated (70). When the NIR-II probe is excited to make the local tissue temperature of tumor exceed 43°C, it will produce irreversible effect of killing tumor cells (7). At present, other than affecting mitochondrial metabolism, there is no definite conclusion on the specific mechanism of PTT.

Evidence has suggested that PTT can activate TRPV1 ion channel in tumor cells and heighten the intracellular Ca²⁺ level, causing mitochondrial dysfunction and apoptosis (71). Thereupon, dysfunctional mitochondria can further whittle the body’s resistance to thermal damage by stimulating the expression of heat shock proteins (72). Promisingly, the especially designed PTA can generally kill tumors by
heating up to more than 43°C in a quick time after sensing NIR laser at the tumor site (Figure 5G). Most NIR-II probes with properly photothermal properties such as TSSI NPs (18), can even achieve tumor ablation completely (Figure 5H).

It should be noticed that PTT is often distinguished from photodynamic therapy (PDT) due to the fact it does not directly depend on cellular oxygen tension. PDT principally relies on photosensitizers to generate reactive oxygen species under light

TABLE 4 Quality assessment of the experiments included in the studies.

| Study          | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Total |
|----------------|---|---|---|---|---|---|---|---|---|----|-------|
| Zhang 2021 (7) | + | NR | NR | + | + | NR | + | + | NR | + | 6     |
| Dai 2021 (8)   | + | NR | + | + | + | NR | + | + | +  | + | 8     |
| Li 2020 (9)    | + | NR | + | + | + | + | + | + | +  | + | 9     |
| Wang 2019 (10) | + | NR | + | + | + | + | + | + | NR | + | 8     |
| Zheng 2021 (14)| + | NR | NR | + | + | NR | + | + | NR | + | 6     |
| Zheng 2020 (15)| + | NR | NR | + | + | NR | + | + | +  | + | 7     |
| Zheng 2020 (16)| + | NR | NR | + | + | NR | + | + | +  | + | 7     |
| Zhao 2020 (17) | + | NR | NR | + | + | NR | + | + | NR | + | 6     |
| Zhang 2020 (18)| + | NR | NR | + | + | NR | + | + | NR | + | 6     |
| Zhang 2020 (19)| + | NR | + | + | + | NR | + | + | NR | + | 7     |
| Zhang 2019 (20)| + | NR | NR | + | + | NR | + | + | NR | + | 6     |
| Yin 2019 (21)  | + | NR | NR | + | + | NR | + | + | +  | + | 7     |
| Yang 2020 (22) | + | NR | + | + | + | + | + | + | +  | + | 9     |
| Xie 2021 (23)  | + | NR | NR | + | + | NR | + | + | NR | + | 4     |
| Wang 2021 (24) | + | NR | + | + | + | + | + | + | +  | + | 8     |
| Sun 2021 (25)  | + | NR | + | + | + | NR | + | + | NR | + | 7     |
| Sun 2020 (26)  | + | NR | + | + | + | + | + | + | +  | + | 9     |
| Shi 2018 (27)  | + | NR | NR | + | + | NR | + | + | NR | + | 6     |
| Li 2021 (28)   | + | NR | NR | + | + | NR | + | + | +  | + | 7     |
| Li 2019 (29)   | + | NR | + | + | + | NR | + | NR | + | +  | 7     |
| Li 2019 (30)   | + | NR | + | NR | + | NR | + | + | NR | + | 6     |
| Li 2021 (31)   | + | NR | NR | NR | + | NR | + | NR | NR | + | 4     |
| Li 2019 (32)   | + | NR | NR | + | + | NR | + | + | +  | + | 7     |
| Li 2021 (33)   | + | NR | + | NR | + | + | + | + | NR | + | 7     |
| Hu 2019 (34)   | + | NR | + | + | + | NR | + | + | +  | + | 7     |
| Dai 2021 (35)  | + | NR | + | NR | + | NR | + | + | NR | + | 6     |
| Chen 2021 (36) | + | NR | + | NR | + | NR | + | + | NR | + | 6     |
| Jia 2021 (37)  | + | NR | NR | + | + | NR | + | NR | + | +  | 5     |
| Qian 2021 (38) | + | NR | + | + | + | NR | + | + | +  | + | 7     |
| Guan 2021 (39) | + | NR | NR | NR | + | NR | + | NR | NR | + | 4     |
| Xia 2020 (40)  | + | NR | + | + | + | NR | + | NR | NR | + | 6     |
| Xu 2020 (41)   | + | NR | + | + | + | NR | + | NR | NR | + | 5     |
| Zhu 2020 (42)  | + | NR | + | + | + | NR | + | NR | NR | + | 6     |
| Yao 2020 (43)  | + | NR | NR | NR | + | NR | + | + | NR | + | 4     |
| Wang 2019 (44) | + | NR | + | + | + | + | + | + | NR | + | 8     |
| Meng 2018 (45) | + | + | NR | + | + | + | + | + | NR | + | 4     |
| Zheng 2021 (46)| + | NR | + | + | + | NR | + | + | +  | + | 7     |
| Huang 2020 (47)| + | NR | NR | NR | + | NR | + | + | NR | + | 6     |
| Zhou 2020 (48) | + | NR | + | + | + | + | + | + | NR | + | 7     |
| Yang 2017 (49) | + | NR | NR | + | + | + | + | + | NR | + | 7     |
| Feng 2019 (50) | + | + | + | + | + | NR | + | + | +  | + | 9     |
| Zhao 2019 (51) | + | NR | + | NR | + | NR | + | + | +  | + | 6     |

1, peer-reviewed publication; 2, statements describing control of temperature; 3, randomization to treatment group; 4, allocation concealment; 5, blinded assessment of outcome; 6, avoidance of anesthetics with known notable intrinsic neuroprotective properties; 7, use of animals with relevant comorbidities; 8, sample size calculation; 9, compliance with animal welfare regulations; 10, declared any potential conflict of interest. +: The article confirms the indicator and gets a point. -: This article does not meet this indicator and this indicator is not scored. NR: No description of the indicator in the article.
irradiation to induce tumor cell death (73). In view of the divergent mechanisms of these two methods, PTT may be more suitable for the treatment of some hypoxic tumor, while PDT is inclined to most effective for hyperoxia tumor (74). Moreover, the intensity of the NIR laser attenuates extensively with the depth of penetration, resulting in a sudden drop in available heat energy for deep tumor mass. This limitation makes PPT more suitable for subcutaneous or other tumors closer to the body surface. In order to amplify the applicability of PTT, the combination of photothermal treatment and PDT, immunotherapy, chemotherapy and gene therapy has been established and achieved remarkable results (75–78).

In this paper, we determined some evidence about the efficacy and safety of PTT for cancer remedy using a meta-analysis method. Whereas there are still some tricky problems need to be solved. First of all, the small sample size and some ineluctable low-quality preclinical researches have discounted the consequences of the meta-analysis to some extent. Secondly, the data available for forest plot analysis is too scarce, so we solely used the cases of...
tumor complete ablation and suppression for correlation analysis. The influence of treatment conditions such as NIR laser intensity and irradiation time needs to be analyzed with more complete research data. Although NIR-II guided PTT is a promising strategy for cancer treatment, there are still many bottlenecks urgently need to be addressed before its clinical application. Sanguinely, we hold that the continuous development of NIR-II imaging technology and nanotechnology will eventually overcome the existing issues and bring more extensive application of PTT in the future.

Conclusions

Based on a meta-analysis of preclinical studies, this paper demonstrated that PTT guided by NIR-II imaging has terrific efficacy and high safety in cancer treatment. Evidence from multiple preclinical data indicated that PTT will be a promising strategy for clinical multi-cancer therapy. Nevertheless, the development of novel NIR-II probes that are more suitable for clinical use is still the core issue of PTT therapy. Meanwhile, the potential multimodal toxicity of probes also requires extensive preclinical and clinical evaluation.

Author contributions

The main conception and design of this paper: FF, YaZ, XM, and XW. Data extraction and sorting: FF, YaZ, YZe, YZh and SZ. Article drafting: FF and YH. Modification and optimization: FF and XW. All authors contributed to the article and approved the submitted version.

Funding

This study was supported by the National Natural Science Foundation of China (82104533 and 81973569), the Science & Technology Department of Sichuan Province (2021YJ0175), and the China Postdoctoral Science Foundation (2020M683273).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
enhancing ROS-feedback synergistic antitumor therapy. ACS Appl Mater Interf (2020) 12:5446. doi: 10.1021/acsami.0c01106.

16. Zheng Z, Chen Q, Dai R, Jia Z, Yang C, Peng X, et al. A continuous stimuliresponsive system for NIR-II fluorescence/photoacoustic imaging guided photothermal/gas synergistic therapy. Nanoscale (2020) 12:11562–72. doi: 10.1039/d0nr02549g.

17. Zhao M, Ding J, Mao Q, Zhang Y, Gao Y, Ye S, et al. A novel on-off(NIR3)- integrin-targeted NIR-II nanoprobe for multimodal imaging guided photothermal therapy of tumors in vivo. Nanoscale (2020) 12:6953–8. doi: 10.1039/cn10720g.

18. Zhang Z, Xu W, Wang M, Wen H, Gao H, Zhang P, et al. An all-round athlete on the track of phototheranostics: Subtly regulating the balance between radiative and nonradiative decays for multimodal imaging-guided synergistic therapy. Adv Mater (2020) 32:e2003210. doi: 10.1002/adma.202003210.

19. Zhang W, Dang W, Zhang H, Sun X, Huang T, Wang W, et al. Biorthogonal-targeted 1064 nm excitation theranostic nanoplatform for precise NIR-Illa fluorescence imaging guided efficient NIR-II photothermal therapy. Biomaterials (2020) 243:119934. doi: 10.1016/j.biomaterials.2020.119934.

20. Zhang W, Sun X, Huang T, Pan X, Sun L, Ji J, et al. 1300 nm absorption two-acceptor semiconductor polymer nanoparticles for NIR-II photoacoustic imaging system guided NIR-II photothermal therapy. Chem Commun (Camb) (2019) 55:2980–3. doi: 10.1039/c9cc04196f.

21. Yin C, Li X, Wen G, Yang B, Zhang Y, Chen X, et al. Organic semiconducting polymer amphiphile for near-infrared-II light-triggered phototheranostics. Biomaterials (2020) 232:119684. doi: 10.1016/j.biomaterials.2020.119684.

22. Yang Y, Fan L, Li L, Yang Y, Nuerhsha A, Yue D, et al. Semiconducting polymer nanomaterials as theranostic system for near-Infrared-II fluorescence imaging and photothermal therapy under safe laser fluence. ACS Nano (2020) 14:2509–21. doi: 10.1021/acsnano.0c00043.

23. Xie L, Li J, Wang G, Sang W, Xu M, Li W, et al. Phototheranostic metal-organic networks with anisoméosal PD-L1 enhanced ferroptosis for synergistic immunotherapy. J Am Chem Soc (2022) 144:778–97. doi: 10.1021/jacs.0c10753.

24. Wang X, Li H, Li P, Fan H, Chen G. Prussian Blue-coated lanthanide-doped core/shell-shell nanocrystals for NIR-II image-guided photothermal therapy. Nanoscale (2019) 11:22079–88. doi: 10.1039/c9nr07937d.

25. Sun P, Jiang X, Sun B, Wang H, Li J, Fan Q, et al. Electron-acceptor density adjustments for preparation conjugated polymers with NIR-II absorption and brighter NIR-II fluorescence and 1064 nm active photothermal/gas therapy. Biomaterials (2022) 280:121319. doi: 10.1016/j.biomaterials.2021.121319.

26. Sun J, Cai W, Sun Y, Gao C, Zhang R. Facile synthesis of melanin-dye nanogel for NIR-II Fluorescence/Photoacoustic guided photothermal therapy. Int J Nanomedicine (2020) 15:10199–213. doi: 10.2147/ijnm.s284520.

27. Shi B, Yan Q, Tang J, Lin K, Zhang J, Zhu Y, et al. Hydrogen sulfide-activatable second near-infrared fluorescent nanomaterials for targeted photothermal cancer therapy. Nano Lett (2018) 18:6411–6. doi: 10.1021/acs.nanolett.8b02767.

28. Li X, Fang S, Sun B, Yin C, Tan J, Wan Y, et al. Near-infrared small molecule coupled with rigidity and flexibility for high-performance multimodal imaging-guided photodynamic and photothermal synergistic therapy. Nanoscale Horiz (2021) 6:177–85. doi: 10.1039/dhm00672f.

29. Li X, Jiang M, Zeng S, Liu H. Polydopamine coated multifunctional lanthanide theranostic agent for vascular malformation and tumor vessel imaging beyond 1500 nm and imaging-guided photothermal therapy. Theranostics (2019) 9:3866–78. doi: 10.7150/thno.31864.

30. Li T, Li C, Ruan Z, Xu P, Yang Y, Yuan P, et al. Polyethylene-conjugated second near-infrared organic fluorophore for image-guided photothermal therapy. ACS Nano (2019) 13:3691–702. doi: 10.1021/acsnano.9b04052.

31. Li J, Xie L, Li B, Yin C, Wang G, Yang W, et al. Engineering a hydrogen-Sulfide-Based nanomodulator to normalize hyperactive photothermal immunomodulation for combination cancer therapy. Adv Mater (2021) 33:e2004841. doi: 10.1002/adma.202004841.

32. Li J, Jiang R, Wang Q, Li X, Hu X, Yuan Y, et al. Semiconducting polymer nanotheranostics for NIR-II/Photoacoustic imaging-guided photothermal initated nitric oxide release. Biomaterials (2019) 217:119304. doi: 10.1016/j.biomaterials.2019.119304.

33. Li J, Wang R, Sun Y, Xiao P, Yang S, Wang X, et al. NIR-II fluorophore with dithienylethene as an electron donor for Fluorescence/Photoacoustic dual-modal imaging and photothermal therapy. ACS Appl Mater Interf (2021) 13:54830–9. doi: 10.1021/acsami.0c17819.

34. Hu X, Tang Y, Hu Y, Yu F, Lu X, Wang Y, et al. Gadolinium-chelated polymer-based nanotheranostics for Photostimulative/Magnetic Resonance/NIR-II fluorescence imaging-guided cancer photothermal therapy. Theranostics (2019) 9:4168–81. doi: 10.7150/thno.34390.

35. Dai Y, Zhao H, He K, Du W, Kong Y, Wang Z, et al. NIR-II excitation photothermal theranostic nanomedicine for Fluorescence/Photoacoustic tumor imaging and targeted photothermal-photonic thermodynamic therapy. Small (2021) 17: e2102527. doi: 10.1002/smll.202102527.

36. Chen Y, Sun B, Jiang X, Yuan Z, Chen S, Sun P, et al. Double-acceptor conjugated polymers for NIR-II fluorescence imaging and NIR-II photothermal therapy applications. J Mater Chem B (2021) 9:1002–8. doi: 10.1039/d0tb0499f.

37. Jia Z. Chemical synthesis of a novel carbon-based nanomaterials and the application in tumor diagnosis and treatment. master. Tsinghua University (2021). doi: 10.27351/d.cnki.gjtsu.2021.001912.

38. Quan H. Anti-aggregation cyanine dyes used in NIR-II imaging-guided photothermal therapy. master. University of Science and Technology of China (2021). doi: 10.27517/d.cnki.gjstc.2021.000112.

39. Guan X. Iron oxide-based nanocomposite for dual-modality ImagingGuided chemical phototherapy and anti-tumor ImmunotherapyyAgainst immune cold triple-negative breast cancer. Inner Mongolia University (2020). doi: 10.27224/d.cnjmu.2020.000955.

40. Yao D, Wang Y, Zou R, Bian K, Liu P, Shen S, et al. Molecular engineered squareane nanoprobe for NIR-II/Photoacoustic imaging and photothermal therapy of metastatic breast cancer. ACS Appl Mater Interf (2020) 12:4276–8. doi: 10.1021/acsami.9b10247.

41. Fan X. Synthesis of conjugated polymer OpticalDiagnostic agents for tumor therapy. master. Nanjing University of Posts and Telecommunications (2019). doi: 10.27517/d.cnjmu.2019.000727.
Fluorescence-guided surgery for hepatoblastoma with indocyanine green.

Methods

Fluorescence imaging in the visible and near-infrared-I/II windows.

Vessel imaging by using lanthanide nanoprobe with enhanced down-shifting emission beyond 1500 nm.

First-in-human liver-tumour surgery guided by multispectral tumor surgery guided by near-Infrared-II fluorescence imaging.

Near-infrared-II fluorescence imaging in the visible and near-infrared-I/II windows.

Hepatocellular carcinoma: Challenges and opportunities for new treatment options.

Near-infrared-I dyes accelerates clinical translation of near-Infrared-II (NIR-II) bioimaging.

ROS in photodynamic therapy.

Second near-infrared (NIR-II) imaging: a novel diagnostic technique for brain diseases.

Biocompatible croconaine dye-peptide for enhanced photo-sonotheranostics of hepatocellular carcinoma.

Synthesis of multi-branched au nanocomposites with distinct plasmon resonance in NIR-II window.

Biodegradable MoTe2 nanosheets for combined photothermal and chemotherapy of gastric cancer.

First-in-human liver-cancer radiotherapy efficacy.

Enhancement of tumor lethality of ROS in photodynamic therapy.

Highly penetrable and on-demand oxygen release with tumor activity composite nanosystem for Photothermal/Photodynamic synergetic therapy.

Biocompatible nanoparticles for combined photothermal and chemotherapy of cancer.

Synthesis of multi-branched au nanocomposites with distinct plasmon resonance in NIR-II window and controlled CRISPR-Ca9 delivery for synergistic gene photothermal therapy.